ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

BFRIW Biofrontera Inc

0.0476
0.00 (0.00%)
09 Aug 2024 - Closed
Delayed by 15 minutes
Name Symbol Market Type
Biofrontera Inc NASDAQ:BFRIW NASDAQ Equity Warrant
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  0.00 0.00% 0.0476 0.03 0.046 100 21:00:00

Biofrontera Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on April 8, 2022

01/04/2022 6:00pm

GlobeNewswire Inc.


Biofrontera (NASDAQ:BFRIW)
Historical Stock Chart


From Aug 2021 to Aug 2024

Click Here for more Biofrontera Charts.

Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today it will report financial results for the three months and full year ended December 31, 2021 before the opening of the U.S. financial markets on Friday, April 8, 2022 and will host a conference call that same day beginning at 11:00 a.m. Eastern time to discuss those results, provide a business update and answer questions.

Conference Call and Webcast Information

Event:Biofrontera Inc. Fourth Quarter and Full Year 2021 Financial Results and Business Update Conference Call
Date:Friday, April 8, 2022
Time:11:00 a.m. Eastern time
Conference call:1-877-877-1275 (U.S.)1-412-858-5202 (international)
Webcast:Live and 90-day replay webcast are available here and at www.investors.biofrontera-us.com.

About Biofrontera Inc.

Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on PDT and topical antibiotics. The Company’s licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit https://www.biofrontera-us.com.

Contacts

Biofrontera Inc.Anke zur Mühlen+1 781 486 1539us-ir@biofrontera.com

LHA Investor RelationsTirth T. Patel+1 212 201 6614tpatel@lhai.com

1 Year Biofrontera Chart

1 Year Biofrontera Chart

1 Month Biofrontera Chart

1 Month Biofrontera Chart

Your Recent History

Delayed Upgrade Clock